All AbMole products are for research use only, cannot be used for human consumption.
Eliglustat inhibits glucosylceramide synthase (GCS), thus reducing the load of glucosylceramide influx into the lysosome.
BioRxiv. 2024 Apr 04;587899.
Vesicle-mediated mitochondrial clearance underlies an actionable metabolic vulnerability in triple-negative breast cancer
Eliglustat purchased from AbMole
Nat Commun. 2020 Aug 27;11(1):4279.
Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer
Eliglustat purchased from AbMole
 |
Source | Nat Commun (2020), Figure 7, Eliglustat (Abmole Bioscience Inc.) |
| Method | intraperitoneal injection | |
| Cell Lines | C57Bl/6N mice | |
| Concentrations | 60 mg/kg | |
| Incubation Time | 15 days | |
| Results | Metabolomics analysis of tumor tissues from all treatment groups showed that eliglustat was linked to reductions in glycosphingolipids in RM-9 tumor bearing mice |
| Molecular Weight | 404.54 |
| Formula | C23H36N2O4 |
| CAS Number | 491833-29-5 |
| Solubility (25°C) | DMSO ≥ 60 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Glucosylceramide Synthase Products |
|---|
| Ibiglustat
Ibiglustat (Venglustat) is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. |
| G43
G43 is a potent, selective glucosyltransferase inhibitor, with the Kd of 3.7μM and 46.9 nM for GtfB and GtfC, respectively. |
| GZ667161
GZ667161 (Genz-667161) is potent, orally available and CNS-penetrant inhibitor of Glucosylceramide synthase (GCS). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
